Favorable results of rituximab in combination with CHOP in the front-line treatment of follicular lymphoma grade 3.

被引：0
|
作者：
Fayad, Luis [1 ]
Overman, Michael [1 ]
Pro, Barbara [1 ]
McLaughlin, Peter [1 ]
Samaniego, Felipe [1 ]
Younes, Anas [1 ]
Romaguera, Jorge Enrique [1 ]
Hagemeister, F. B. [1 ]
Kwak, Larry [1 ]
Rodriguez, Maria Alma [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
10.1182/blood.V108.11.2770.2770
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2770
引用
收藏
页码：784A / 784A
页数：1
相关论文
共 50 条
  • [31] The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma
    Overman, M. J.
    Feng, L.
    Pro, B.
    McLaughlin, P.
    Hess, M.
    Samaniego, F.
    Younes, A.
    Romaguera, J. E.
    Hagemeister, F. B.
    Kwak, L.
    Cabanillas, F.
    Rodriguez, M. A.
    Fayad, L. E.
    ANNALS OF ONCOLOGY, 2008, 19 (03) : 553 - 559
  • [32] Efficacy and infection morbidity of front-line immuno-chemotherapy in follicular lymphoma
    Djebbari, Faouzi
    Kaji, Furqaan
    Stanton, Louise
    Lawrence, Megan M.
    Collins, Graham P.
    Eyre, Toby A.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2020, 105 (05) : 667 - 671
  • [33] A cost-effectiveness analysis of front-line treatment strategies in early-stage follicular lymphoma
    Tobin, Joshua W. D.
    Crothers, Anna
    Ma, Ti Eric
    Mollee, Peter
    Gandhi, Maher K.
    Scuffham, Paul
    Hapgood, Greg
    LEUKEMIA & LYMPHOMA, 2021, 62 (14) : 3484 - 3492
  • [34] The association of rituximab with CHOP in first-line treatment brings a significant benefit in the advanced stages of follicular lymphoma
    Choquet, Sylvain
    HEMATOLOGIE, 2006, 12 (01): : 13 - 14
  • [35] Comparison of first-line treatment with bendamustine plus rituximab versus R-CHOP for patients with follicular lymphoma grade 3A: Results of a retrospective study from the Fondazione Italiana Linfomi
    Margiotta-Casaluci, Gloria
    Bigliardi, Sara
    Cocito, Federica
    Meli, Erika
    Petrucci, Luigi
    Nicolosi, Maura
    Annibali, Ombretta
    Boccomini, Carola
    Bozzoli, Valentina
    Castellino, Alessia
    Cattina, Federica
    Cenfra, Natalia
    Ciavarella, Sabino
    Kovalchuk, Sofya
    Rotondo, Francesco
    Fama, Angelo
    Olivieri, Jacopo
    Zaja, Francesco
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [36] Combination of Ibrutinib with Rituximab Versus Placebo with Rituximab for First-Line Treatment of Follicular Lymphoma: PERSPECTIVE, a Randomized Phase 3 Study
    Flinn, Ian
    Gordon, Leo
    Rule, Simon
    Chen, Robert
    Kwei, Long
    Chu, Alvina D.
    Fowler, Nathan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S277 - S278
  • [37] The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome
    Buske, Christian
    Hoster, Eva
    Dreyling, Martin
    Hasford, Joerg
    Unterhalt, Michael
    Hiddemann, Wolfgang
    BLOOD, 2006, 108 (05) : 1504 - 1508
  • [38] BACOP/FR combination chemotherapy as front-line treatment of follicular lymphoma. A phase II study of the Gruppo Italiano Studio Linfomi (GISL).
    Luminari, S.
    Lombardo, M.
    Mammi, C.
    Bellei, M.
    Merli, F.
    Stelitano, C.
    Lazzaro, A.
    Marasca, R.
    Brugiatelli, M.
    Federico, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 439S - 439S
  • [39] Rituximab Improves the Outcome of Patients With Grade 3 Follicular Lymphoma
    Yuan, Ji
    Greiner, Timothy
    Fu, Kai
    Smith, Lynette
    Weisenburger, Dennis
    MODERN PATHOLOGY, 2015, 28 : 390A - 390A
  • [40] Rituximab Improves the Outcome of Patients With Grade 3 Follicular Lymphoma
    Yuan, Ji
    Greiner, Timothy
    Fu, Kai
    Smith, Lynette
    Weisenburger, Dennis
    LABORATORY INVESTIGATION, 2015, 95 : 390A - 390A
12345